The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.
about
The roles of stem cell memory T cells in hematological malignanciesAdvances in the management of gastrointestinal cancers--an upcoming role of immune checkpoint blockadeCatching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas?Lower expression of PD-1 and PD-L1 in peripheral blood from patients with chronic ITP.The miR-25-93-106b cluster regulates tumor metastasis and immune evasion via modulation of CXCL12 and PD-L1.Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.Combination therapy of cancer with cancer vaccine and immune checkpoint inhibitors: A mathematical modelEffects of programmed death-ligand 1 expression on OK-432 immunotherapy following transurethral resection in non-muscle invasive bladder cancerInterleukin-7 and anti-programmed cell death 1 antibody have differing effects to reverse sepsis-induced immunosuppression.PD-L1 over-expression and survival in patients with non-small cell lung cancer: a meta-analysis.Enhancement of the TCRζ expression, polyclonal expansion, and activation of t cells from patients with acute myeloid leukemia after IL-2, IL-7, and IL-12 induction.T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment.Differential induction of PD-1/PD-L1 in Neuroimmune cells by drug of abuse.Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.Hepatitis C Virus Induces MDSCs-Like Monocytes through TLR2/PI3K/AKT/STAT3 Signaling.The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors.Arsenic induced complete remission in a refractory T-ALL patient with a distinct T-cell clonal evolution without molecular complete remission: A case report.PD-1 blockade enhances the vaccination-induced immune response in gliomaPrevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways.PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Elevated Th22 cells correlated with Th17 cells in peripheral blood of patients with acute myeloid leukemia.Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.The role of the immunosuppressive microenvironment in acute myeloid leukemia development and treatment.The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy.Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Novel ALK inhibitors in clinical use and development.Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy.ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development.Control of local immunity by airway epithelial cells.The immune system and cancer evasion strategies: therapeutic concepts.Cancer Immunotherapy: Selected Targets and Small-Molecule Modulators.Urothelial Cancer: Inflammatory Mediators and Implications for Immunotherapy.Progress and opportunities for immune therapeutics in osteosarcoma.Diagnosis and treatment of CD20 negative B cell lymphomas.The role of PD-1 in regulation of macrophage apoptosis and its subversion by Leishmania donovani.Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
P2860
Q26783681-378D2436-3D93-4FBD-9EA3-5FECA757024AQ26801856-07EB1D76-04F9-440E-B97E-5318202FE565Q28076071-23431CA3-9EB9-4D82-9BD2-1110626E2C2CQ33431511-04DE3DCD-61ED-4BB8-8EC0-6D288040E4AEQ33591618-C129C725-41F6-4E92-98BE-DC18DE5C71A3Q33593877-46481638-FF2C-4FA7-9C73-2E7BA4D261A9Q33638083-62D6F7EA-D166-4E9E-9DA5-3B8A2A11A3A4Q33728672-0BDFBB05-486D-462A-BF07-3E0025DA4BD4Q33751253-77868EB3-37B5-4C56-99FC-22175CD59D58Q35177535-5BE0E999-AF47-4981-AC83-CF0C258C6B7AQ35256558-4B9572BB-E3D2-491C-8FA5-A5F505BA07CDQ35857271-29ECC89A-168A-48F7-BF71-CA4760AC851AQ35899277-4F1A2292-1640-4F42-BAD2-D6BE11FE70C1Q35997650-EE82C76A-265B-469A-963D-1F4A5F65644CQ36131489-4AD88AA7-8829-4729-8F7B-2CC180BCC70AQ36257528-E6F3E23A-BFD7-426F-9AC2-EEA6991B09B3Q36270334-4D98C566-CBB0-42A9-B39F-48C31BB1964FQ36954651-4E738848-2150-41D2-B705-8CC0A582F6D4Q37109193-87A08E21-11AE-461C-BD84-3BFF50FBF0F9Q37277855-8AD6A979-C3E0-4A3A-B1F8-273A15B95871Q37565475-688D0933-BEF6-468C-A592-3AC749A9B10FQ37645126-F483834F-CC50-4F5D-8805-43877A674B5CQ37686620-281D3688-70D9-49F4-A8A2-F4A7B6E9C89EQ38250205-D5FAEB2C-8445-4E84-8AB9-02AD8AC8A516Q38261285-DDB818C5-AF1A-48CB-9197-77E7587DDC60Q38285859-4DA03270-85CB-4995-B4F2-63BEDD9FA4DAQ38368587-1B0113B0-0877-414C-AF6D-C40C06759558Q38427240-35661622-6B83-4208-9C8C-E1B0C233D4DDQ38466376-6720E9E0-D35D-4F10-BCC8-FCA553BE2930Q38557033-379016A4-5712-4019-93C8-C3704B1BF473Q38558611-A3C87C31-CA66-4915-B5EB-7A698C510D05Q38640917-C2638F83-22E4-4D89-8C7B-AA76E9F865D8Q38655955-217A9373-7C3A-4799-95F7-C1FEB995C763Q38691172-F177747D-037F-4011-AF88-57320009B2A7Q38719858-E71CE9D4-1A30-4CDE-B4DF-9F4077B1A371Q38833996-19B47B04-A27F-42C9-947E-5D994B070E44Q38948905-C59DB380-BEDD-4E80-977A-15B6DDC5C412Q39132786-AF6BDB21-B06B-44B0-972C-B54064089E48Q40142319-C91811BD-2DAD-48D0-8904-39CDD1ABBB9BQ40517920-BB42D184-0516-4D82-810A-C3E2477013DF
P2860
The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The role of PD-1 and PD-L1 in ...... th hematological malignancies.
@en
The role of PD-1 and PD-L1 in ...... th hematological malignancies.
@nl
type
label
The role of PD-1 and PD-L1 in ...... th hematological malignancies.
@en
The role of PD-1 and PD-L1 in ...... th hematological malignancies.
@nl
prefLabel
The role of PD-1 and PD-L1 in ...... th hematological malignancies.
@en
The role of PD-1 and PD-L1 in ...... th hematological malignancies.
@nl
P2093
P2860
P921
P356
P1476
The role of PD-1 and PD-L1 in ...... th hematological malignancies.
@en
P2093
Lijian Yang
Shaohua Chen
Yangqiu Li
P2860
P2888
P356
10.1186/1756-8722-6-74
P5008
P577
2013-09-30T00:00:00Z
P5875
P6179
1051135651